These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27716212)

  • 1. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
    Southworth T; Plumb J; Gupta V; Pearson J; Ramis I; Lehner MD; Miralpeix M; Singh D
    Respir Res; 2016 Oct; 17(1):124. PubMed ID: 27716212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
    Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
    Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
    Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
    J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells.
    Khan A; Southworth T; Worsley S; Sriskantharajah S; Amour A; Hessel EM; Singh D
    Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):932-940. PubMed ID: 28508433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease.
    Gupta S; Yamada E; Nakamura H; Perez P; Pranzatelli TJ; Dominick K; Jang SI; Abed M; Martin D; Burbelo P; Zheng C; French B; Alevizos I; Khavandgar Z; Beach M; Pelayo E; Walitt B; Hasni S; Kaplan MJ; Tandon M; Magone MT; Kleiner DE; Chiorini JA; Baer A; Warner BM
    Ann Rheum Dis; 2024 Jul; 83(8):1034-1047. PubMed ID: 38527764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
    Johnson B; Cheng L; Koenitzer J; Catlett IM; Schafer P
    Front Immunol; 2024; 15():1437512. PubMed ID: 39403378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
    Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
    Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
    Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
    Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
    Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
    Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
    Chen S; Paveley R; Kraal L; Sritharan L; Stevens E; Dedi N; Shock A; Shaw S; Juarez M; Yeremenko N; Baeten D; Payne A
    J Autoimmun; 2020 Jul; 111():102435. PubMed ID: 32360069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma.
    Matsunaga Y; Inoue H; Fukuyama S; Yoshida H; Moriwaki A; Matsumoto T; Matsumoto K; Asai Y; Kubo M; Yoshimura A; Nakanishi Y
    Biochem Biophys Res Commun; 2011 Jan; 404(1):261-7. PubMed ID: 21111712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Janus kinase inhibitors for skin disorders].
    Solimani F; Ghoreschi K
    Dermatologie (Heidelb); 2024 Oct; 75(10):781-790. PubMed ID: 39212722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
    Ibrahim SSA; Salama MA; Selima E; Shehata RR
    Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
    LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
    Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
    Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
    Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
    Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
    Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.